A phase 2 randomized controlled trial of the efficacy and safety of Cannabidivarin as add-on therapy in participants with inadequately controlled focal seizures - Brodie, M J; Czapinski, P; Pazdera, L; GWEP1330 Study Group (Cannabis Cannabinoid Res, 2021)